Clarus Biologics
Clarus Biologics specializes in the discovery and development of novel vaccine and immunology technologies, with a focus on increasing the availability of safe, effective prophylactic and therapeutic solutions. The company develops next-generation virus-like particle (VLP) adjuvants to enhance vaccine immune responses, improve efficacy, enable dose sparing, and expand vaccine applicability, especially for populations with impaired immunity and challenging pathogens.
Industries
N/A
Clarus Biologics
5151 McCrimmon Parkway Suite 240, Morrisville, NC 27560, USA
Products
A novel virus-like particle adjuvant platform designed to enhance adaptive and innate immune responses when combined with subunit, recombinant, or inactivated vaccine antigens. Increases vaccine efficacy, enables mucosal immunity, and allows for dose sparing.
A novel virus-like particle adjuvant platform designed to enhance adaptive and innate immune responses when combined with subunit, recombinant, or inactivated vaccine antigens. Increases vaccine efficacy, enables mucosal immunity, and allows for dose sparing.
Expertise Areas
- Vaccine adjuvant research
- Immunotherapy platform development
- Pre-clinical vaccine efficacy studies
- Mucosal immunology
Key Technologies
- Virus-like particle (VLP) platform
- Alphavirus-based vectors
- Mucosal immune activation
- Antigen-specific immune response enhancement
Key People
Chief Scientific Officer and Co-Founder
Chief Technology Officer and Co-Founder
Chief Executive Officer
Chief Scientific Officer and Co-Founder
Chief Technology Officer and Co-Founder
Chief Executive Officer
News & Updates
Article discusses the rationale and mechanism behind Clarus Biologics' two-component immunology strategy using virus-like particles and separate antigenic mass to maximize immune response and vaccine efficacy.
Article discusses the rationale and mechanism behind Clarus Biologics' two-component immunology strategy using virus-like particles and separate antigenic mass to maximize immune response and vaccine efficacy.